| P2093 | author name string | Oliver Sartor | |
| | Przemyslaw Twardowski | |
| | Sumanta Kumar Pal | |
| P2860 | cites work | Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Base | Q53817252 |
| | New Therapies for Castration-Resistant Prostate Cancer | Q55053398 |
| | Taxol-induced polymerization of purified tubulin. Mechanism of action | Q72498816 |
| | Dynamic properties of microtubules at steady state in the presence of taxol | Q72539217 |
| | Bicalutamide for advanced prostate cancer: the natural versus treated history of disease | Q73585204 |
| | Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers | Q80611754 |
| | Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease | Q84556406 |
| | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study | Q24596926 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Isolation of a human prostate carcinoma cell line (DU 145) | Q34255312 |
| | Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. | Q34798892 |
| | Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. | Q35045144 |
| | Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th | Q35549709 |
| | Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 |
| | Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer | Q36504117 |
| | Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer | Q36849649 |
| | Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy | Q37125330 |
| | Larotaxel: broadening the road with new taxanes | Q37551909 |
| | Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma | Q39477765 |
| | Effects of a microtubule stabilizing agent on the response of platelets to vincristine | Q40087213 |
| | Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours | Q40389914 |
| | Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer | Q41072693 |
| | Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes | Q43068334 |
| | Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer | Q43222711 |
| | Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | Q44018378 |
| | Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors | Q46160687 |
| | Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa | Q46589653 |
| | A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients | Q46627004 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | taxoids | Q7689669 |
| | antineoplastic | Q2853144 |
| | prostate neoplasm | Q56014511 |
| P304 | page(s) | 395-402 | |
| P577 | publication date | 2010-12-03 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Critical appraisal of cabazitaxel in the management of advanced prostate cancer | |
| P478 | volume | 5 | |